Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis
Background Although human epidermal growth factor receptor 2 (ERBB2/HER2) is a validated therapeutic target, the significance of ERBB3 (HER3) alterations across solid tumours remains poorly defined. We characterised such alterations to clarify the genomic landscape relevant to HER3-directed strategies, distinguishing s...